(Total Views: 761)
Posted On: 12/09/2021 9:08:56 AM
Post# of 154119
This PR is significant in my mind as it signals the FDA hit piece is in the past, the door is still open here - lends credence back to the company both here & abroad - this could be a sentiment changer (& potentially game changer) - not just for Covid but all their indications.
This excerpt can't be emphasized enough:
"During recent discussions with the FDA, the agency suggested that developing leronlimab for critically ill COVID-19 patients in current situation in U.S. appears feasible"
2022 - year of the tiger - let's goooooo - https://www.youtube.com/watch?v=btPJPFnesV4
This excerpt can't be emphasized enough:
"During recent discussions with the FDA, the agency suggested that developing leronlimab for critically ill COVID-19 patients in current situation in U.S. appears feasible"
2022 - year of the tiger - let's goooooo - https://www.youtube.com/watch?v=btPJPFnesV4
(19)
(0)
